Dr. Beaupre is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Phone+1 813-974-0706Fax+1 813-974-4325
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1999 - 2003- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1997 - 1999
McGovern Medical School at UTHealthClass of 1997
Certifications & Licensure
FL State Medical License 1998 - 2025
Clinical Trials
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2005 Aug 01
- Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Start of enrollment: 2011 Feb 01
- Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 325 citationsLong-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Michael L. Wang, Kristie A. Blum, Peter Martin, Andre Goy, Rebecca Auer
Blood. 2015-08-06 - 1216 citationsTargeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaMichael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer
The New England Journal of Medicine. 2013-08-07 - 97 citationsIbrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan
Blood. 2019-09-26
Press Mentions
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024October 25th, 2024- IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaSeptember 23rd, 2024
- IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 10th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
